Leerink Partners initiated coverage on Stryker with a new price target
$SYK
Medical/Dental Instruments
Health Care
Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2026 | $410.00 | Outperform | Leerink Partners |
| 2/20/2026 | Outperform | William Blair | |
| 1/27/2026 | $387.00 | Hold | TD Cowen |
| 1/6/2026 | $418.00 | Mkt Perform → Outperform | Raymond James |
| 12/19/2025 | $440.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 9/18/2025 | $420.00 | Neutral | Rothschild & Co Redburn |
| 2/26/2025 | $450.00 | Buy | Citigroup |
| 12/2/2024 | $370.00 → $445.00 | Equal-Weight → Overweight | Morgan Stanley |
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
8-K/A - STRYKER CORP (0000310764) (Filer)
SCHEDULE 13G/A - STRYKER CORP (0000310764) (Subject)
DEFA14A - STRYKER CORP (0000310764) (Filer)
Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. The acquisition will strengthen Stryker's Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker's existing PV offerings and support the company's strategy to expand its presence in arterial disease treatment
Portage, Michigan, April 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2026 on Thursday, April 30, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2026. Stryker will host a webcast at 4:30 p.m. ET on Thursday, April 30, 2026, to discuss its first quarter 2026 results. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours afte
Portage, Michigan, March 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Nick Mead has been appointed Vice President, Investor Relations, effective May 1, 2026. Mead has nearly 20 years of experience at Stryker, with leadership roles spanning multiple divisions and business units across the company. Most recently, he served as Vice President, Finance for Stryker's Medical division, where he partnered closely with senior leaders to support commercial strategy, capital allocation and operational execution. "Nick brings deep institutional knowledge, strong financial expertise and a proven ability to support strategic decision making
Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00
William Blair initiated coverage of Stryker with a rating of Outperform
TD Cowen resumed coverage of Stryker with a rating of Hold and set a new price target of $387.00
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15
Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 17.5 % 0.9 % 16.6 % 4.0 % 12.6 %
Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France. Known for its state-of-the-art operations and technical capabilities, the Cestas facility will play a central role in VB Spine's global manufacturing strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106463289/en/VB Spine's manufacturing facility in Cestas, France This milestone expands on the April 1, 2025 formation of VB Spine, established through the acquisition of Stryker's U.S. spine implan
GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s
Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy
Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev